The analyst notes that the first-generation complement inhibitors validate complement as a viable drug target but leave the door open for improvements. 

With DNTH103 advancing in multiple Phase 2 studies and preliminary Phase 1 data demonstrating a meaningful extension of half-life, Wedbush sees the generalized myasthenia gravis (gMG) opportunity as most attractive. 

Wedbush initiates with an Outperform rating and a price target of $23.

The analyst notes that complement inhibition remains a sought-after development area and sees DNTH103 as a promising candidate.

Acknowledging the dysregulated complement pathway's role in autoimmune diseases has made it a highly sought-after target in the pharmaceutical industry. The field remains intensely active, with three acquisitions of complement-focused public companies occurring in the last three years. 

Complement inhibition continues to be regarded as a "hot" therapeutic area due to its potential in addressing various autoimmune conditions and maintaining substantial market interest and investment.

Price Action: DNTH shares are up 1.14% at $11.50 on the last check Wednesday.